N
Neuphoria Therapeutics Inc. (NEUP)
4.10
0.00 (0.00%)
Get all premium features to the best stock analysis tool
4.10
0.00 (0.00%)
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 9.04 | 6.05 | 10 | |
| Quick ratio | 9.04 | 5.63 | 10 | |
| Debt to Equity | 0.00 | 0.30 | 10 | |
| Debt to Assets | 0.00 | 1.04 | 10 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 8.2 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 191K | N/A | N/A | 16M | 16M |
| Gross Profit | N/A | -446K | -663K | 15M | 15M |
| Operating Income | -20M | -15M | -18M | -1M | -204K |
| Net Income | -16M | -14M | -15M | -370K | 1M |
| EBITDA | -19M | -14M | -17M | -466K | 455K |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | -100 | 55.56 | 5.5 |
| Next quarter | N/A | N/A | 1.0 |
| Current year | -100 | -1669.57 | 1.0 |
| Next year | N/A | 40.29 | 5.5 |
| Weighted average score | 3.3 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | 118.82 | 87.3 | -70.08 | 7.8 |
| Y/Y | 999 | 331.63 | 72.14 | -45.59 | 7.8 |
| 3y average | 632.67 | 32.92 | 42.51 | 29.67 | 10 |
| 5y average | 559.4 | -16.08 | 4.43 | -41.83 | 4.0 |
| Weighted average score | 7.4 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $22.3M significantly exceed its total debt $33.5K, ensuring strong financial flexibility
Total current assets $23.4M exceed Total current liabilities $2.6M, highlighting excellent liquidity
Debt-to-equity ratio (0.0) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$6.5M limits the company's ability to reinvest or pay down debt